1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Angel Studios amended and restated its merger agreements to acquire Tuttle Twins Show, LLC (TTS) and Toothy Cow Productions, LLC (TCP), both signed November 14, 2025. The changes extend the outside date to October 31, 2026, and alter several closing conditions and the TCP merger structure. Company insiders and affiliates hold units in both companies and would receive Class A shares in the deals, and the company has already provided funding to both.
Outside date for both the TTS and TCP mergers extended to October 31, 2026
Closing condition requiring a showrunner agreement for Daniel Harmon removed from the TTS deal
Company related parties own 41.6% of TTS units and 2.4% of TCP units as of June 23, 2026
Company has provided $11.7 million to TTS and $11.9 million to TCP to date, with a maximum TCP funding commitment of $11.9 million
Rani Therapeutics appointed Nicholas M. Maestas as Chief Financial Officer, succeeding Svai Sanford, who had previously announced he would step down once a successor was named. The company also approved a 2026 Equity Inducement Plan reserving 5,500,000 Class A shares for new-hire awards, which does not require stockholder approval.
Maestas, age 46, was CFO and Head of Corporate Strategy at Tempest Therapeutics from January 2025 until June 2026.
Offer letter dated June 24, 2026 sets an annual base salary of $500,000 and a target bonus of 75% of base salary.
Maestas will receive a non-qualified option to purchase 2,000,000 Class A shares, vesting over four years.
The Board approved the Inducement Plan on June 28, 2026, reserving 5,500,000 shares.
OceanFirst Financial Corp. completed the sale of $1.3 billion of multifamily loans acquired in its recent Flushing Financial acquisition, reducing exposure to rent-regulated properties. The company said the purchase price was consistent with valuation estimates disclosed when the acquisition was announced, and it will report further balance sheet details in its second quarter earnings release.
Sold more than 1,400 multifamily loans with an aggregate balance of $1.3 billion
Rent-regulated collateral accounted for $736 million of the sold portfolio
Exposure to loans with greater than 50% rent-regulated units now less than 2.5% of total assets
Loans were originated by Flushing Bank and acquired through the merger on June 1, 2026
On June 27, 2026, Martin Marietta agreed to acquire all equity interests in Lhoist North America from LNA Holding for $13.5 billion, consisting of $7 billion in cash and 10,953,543 newly issued Martin Marietta shares valued at $6.5 billion. After closing, LNA Holding is expected to hold about 15% of Martin Marietta's common stock, and the company has a $7.0 billion bridge loan commitment to fund the cash portion, so shareholders would face a larger share count and significant new borrowing if the deal closes.
Total consideration is $13.5 billion: $7 billion in cash plus 10,953,543 shares valued at $6.5 billion, based on the 15-day volume-weighted average price ending June 26, 2026
Closing requires expiration or termination of the Hart-Scott-Rodino waiting period and other regulatory approvals; long stop date is October 31, 2026, extendable to June 15, 2027
Martin Marietta would pay a $350 million termination fee if the deal ends under specified circumstances tied to failure to obtain regulatory clearances by the Extended Long Stop Date
A 364-day, $7.0 billion unsecured bridge facility from Goldman Sachs Bank USA and Goldman Sachs Lending Partners LLC is committed to finance the cash consideration
Globe Life signed a new $450 million term loan and a third amended credit agreement on June 26, 2026, with Wells Fargo replacing Bank of America as administrative agent. The filing shows the company extended its borrowing arrangements, with the term loan maturity moved to June 26, 2029 and the credit agreement maturity moved to June 26, 2031.
Term loan principal increased from $250 million to $450 million, with maturity extended from August 15, 2027 to June 26, 2029.
Credit agreement maturity extended from March 29, 2029 to June 26, 2031.
Wells Fargo, National Association replaces Bank of America, N.A. as administrative agent under both agreements.
The filing does not state the credit agreement's total commitment amount.
Four Corteva directors, Karen Grimes, Marcos Lutz, Charles Magro and Kerry Preete, agreed to resign from the Corteva board effective immediately before the planned spin-off of the seed business into Vylor, Inc. The filing says each is expected to join the Vylor board, and the resignations are not tied to any disagreement with the company. The companies also announced their post-separation boards, and the separation remains on track for the fourth quarter of 2026.
Resignations agreed June 26, 2026, and take effect only if the spin-off is completed
Greg Page to chair a nine-person Corteva board; Luke Kissam to join at separation
Karen Grimes to chair a seven-director Vylor board; a search is ongoing for at least one more member
Vylor filed its first Form 10 registration statement with the SEC; separation on track for 4Q 2026
Andersen Tax LLC, an indirect subsidiary of Andersen Group Inc., entered into a $50.0 million asset-based revolving credit agreement with JPMorgan Chase Bank, N.A. on June 25, 2026. The facility matures three years from closing, bears interest at Term SOFR plus 175 basis points, and is guaranteed by Andersen Group Inc. and other Loan Parties, secured by a first lien on their assets. The filing does not report any change in reported revenue or earnings, but it sets new borrowing capacity and restrictions on distributions and acquisitions for the group.
$50.0 million revolving credit facility dated June 25, 2026, maturing three years from the Closing Date
Interest at Term SOFR plus 175 basis points; unused line fee of 25 basis points per annum
Springing minimum fixed charge coverage ratio of 1.00x applies if availability falls below 25% of the line cap
Domestic acquisitions limited to $25 million in total consideration; foreign acquisitions capped at $15 million per transaction and $75 million per year
Protara Therapeutics said its Chief Medical Officer, Leonardo Viana Nicacio, M.D., resigned to explore other opportunities, effective June 26, 2026. His duties will be taken over by Carla Beckham, M.D., and will continue under the oversight of Jacqueline Zummo, Ph.D., the company's Chief Research & Development Officer.
Leonardo Viana Nicacio, M.D., Chief Medical Officer, resigned effective June 26, 2026, to explore other opportunities
Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, will assume Dr. Nicacio's duties
Jacqueline Zummo, Ph.D., Chief Research & Development Officer, will oversee the work
TransAct Technologies appointed Troy W. Ingianni, formerly Vice President, Global Controller and Chief Accounting Officer at Barnes Group, as Chief Financial Officer, Secretary and Treasurer effective July 1, 2026, replacing Steven DeMartino, who retires from those roles June 30, 2026. The Board's earlier choice of Controller Robert Campbell for the role was withdrawn for personal reasons, and Mr. Ingianni also takes over as Principal Accounting Officer.
Ingianni's offer letter sets a base salary of $350,000 (prorated for 2026) and a target bonus of 35% of base salary.
He will receive 15,000 restricted stock units vesting in four equal annual installments.
Severance is six months' base salary for termination without cause, or 12 months' base salary following a change in control.
John M. Dillon, CEO, will also take the title of President upon DeMartino's retirement.
Meritage Homes signed the Twelfth Amendment to its credit agreement on June 24, 2026, increasing the facility size to $980.0 million and extending maturity from July 9, 2030 to June 24, 2031. The amendment also lets the facility grow to $1.470 billion under certain conditions and revises the adjusted SOFR rate, giving the company a larger, longer-dated borrowing line.
Facility size increased to $980.0 million
Accordion feature permits an increase to $1.470 billion, subject to certain conditions
Maturity extended from July 9, 2030 to June 24, 2031
Amendment signed June 24, 2026; full terms filed as Exhibit 10.1
GD Culture Group Limited's 1-for-250 reverse stock split took effect June 29, 2026, and its common stock began trading on the Nasdaq Capital Market on a split-adjusted basis under the symbol GDC. The filing says issued and outstanding common shares fell from about 1.04 billion to about 4.16 million, plus shares issued for fractional interests. The company states the split does not alter any stockholder's percentage interest, except for adjustments from rounding up fractional shares.
Reverse split effective at market open on June 29, 2026; new CUSIP 19200A303
Issued and outstanding common shares reduced from about 1.04 billion to about 4.16 million, plus fractional-share adjustments
Board authorized the split by unanimous written consent on June 16, 2026; Certificate of Change filed with Nevada on June 18, 2026
Stockholders approved a split ratio between 1-for-2 and 1-for-250 at the December 31, 2025 annual meeting
Midera Food Processing, a Middleby subsidiary, entered a five-year, $1.0 billion revolving credit agreement with Bank of America as administrative agent on June 29, 2026, in connection with its planned spin-off. The Borrower used borrowings and cash on hand to make a $233 million distribution to a Middleby subsidiary, and the spin-off is expected to take effect July 6, 2026, which means shareholders of Middleby will receive Midera shares and Midera will carry this new debt.
$1.0 billion facility: $750 million U.S. dollar revolver and $250 million multi-currency revolver, maturing June 29, 2031.
Before the spin-off takes effect, borrowings may not exceed $300 million; if the spin-off does not occur, commitments terminate within 15 business days.
The Borrower used borrowings and cash on hand to make a $233 million distribution to Middleby Marshall Inc., a Middleby subsidiary.
Middleby shareholders of record at 12:01 a.m. Eastern Time on July 6, 2026 are expected to receive Midera shares.
AeroVironment reported fiscal fourth-quarter 2026 revenue of $641.6 million, up 133% from $275.1 million, and net income of $63.2 million, or $1.25 per diluted share. For the full fiscal year, revenue rose 141% to $1,976.8 million, but the company posted a net loss of $265.1 million, or $5.40 per share, after a $240.7 million goodwill impairment. For fiscal 2027, the company expects revenue of $2.125 billion to $2.225 billion and net income of $8 million to $24 million.
Q4 fiscal 2026 revenue of $641.6 million; net income of $63.2 million, or $1.25 per diluted share, versus $16.7 million, or $0.59, a year earlier
Full-year fiscal 2026 net loss of $265.1 million, or $5.40 per diluted share, including a $240.7 million goodwill impairment
Fiscal 2027 guidance: revenue of $2.125 billion to $2.225 billion; net income of $8 million to $24 million; GAAP EPS of $0.16 to $0.48
Funded backlog of $1.2 billion as of April 30, 2026, versus $726.6 million a year earlier
BillionToOne entered a 12-year lease on about 62,659 square feet of office and laboratory space in Union City, California, with base rent of about $46.7 million over the term. The space is meant to add lab capacity for oncology products because test volumes have exceeded the company's plan over the last year, and the company says the facility will expand its total facility space by about 16%. The lease is anticipated to start on or about August 1, 2027.
Lease with Whipple Road Portfolio, LLC signed June 23, 2026, for 3260 Whipple Road, Union City, CA
Aggregate base rent of about $46.7 million over the 12-year term, with a 12-month rent abatement and a tenant improvement allowance of up to $12.5 million
Security deposit of $407,910 payable on signing; lease option to extend 10 years at prevailing market rate
Expected commencement on or about August 1, 2027; full lease text to be filed with the Form 10-Q for the period ended June 30, 2026
Synchrony Financial announced executive leadership changes effective June 29, 2026. Carol Juel, formerly Executive Vice President, Chief Technology and Operating Officer, becomes Executive Vice President and Chief Executive Officer of the Digital platform, succeeding Bart Schaller, who plans to retire after a 35-year career. The company also promoted Florin Arghirescu to Chief Technology Officer and expanded DJ Casto's role to include Operations.
Carol Juel named EVP and CEO of the Digital platform, succeeding Bart Schaller, effective June 29, 2026
Florin Arghirescu promoted to EVP and Chief Technology Officer, reporting to CEO Brian Doubles
DJ Casto appointed EVP, Chief People and Operations Officer, adding servicing, collections and customer care to Human Resources
Alpex Acquisition Corp, a blank check company, closed its initial public offering of 11,500,000 units at $10.00 per unit on June 26, 2026, including full exercise of the underwriters' over-allotment option, for gross proceeds of $115,000,000. The filing says $115,000,000 was placed in a trust account, which will not be released until a business combination, a shareholder-approved redemption event, or the redemption of public shares if no combination is completed within 12 months.
IPO closed June 26, 2026: 11,500,000 units at $10.00 per unit, gross proceeds of $115,000,000, including 1,500,000 over-allotment units
Private sale of 187,500 units to Sponsor Hugreat Ltd for $1,875,000; 230,000 Class A shares issued to underwriter D. Boral Capital LLC
Three directors appointed June 25, 2026 (Joy Yi Hua, Xin Yue Jasmine Geffner, Yuanmei Ma); $115,000,000 placed in trust
Units began trading on Nasdaq under ALPXU on June 25, 2026
Seaport Entertainment Group's executive vice president, general counsel and corporate secretary, Lucy Fato, left that role effective June 25, 2026, in a termination without cause. She will serve as an advisor to the CEO and remain employed through August 24, 2026. Her separation payments are subject to a release and to her providing the agreed services through that date; the filing does not state payment amounts.
Effective June 25, 2026, Lucy Fato ceased to serve as EVP, General Counsel and Corporate Secretary
Fato will be an advisor to CEO Matthew M. Partridge's office through the Separation Date of August 24, 2026
Separation is a termination without cause under her employment agreement, with payments subject to a release and continued services
Terms are set out in a Letter Agreement dated June 25, 2026, filed as Exhibit 10.1
Concentrix reported fiscal second-quarter 2026 results for the period ended May 31, 2026, with revenue up 1.9% to $2.46 billion, but operating income fell 35.7% to $95.4 million and non-GAAP diluted EPS fell 2.6% to $2.63. The company guided to non-GAAP diluted EPS of $10.83 to $11.18 for the full fiscal year, and expects adjusted free cash flow of $630 million to $650 million, while reporting no share repurchases in the quarter.
Revenue was $2,462.5 million, up 1.9% as reported and 0.6% in constant currency, versus $2,417.4 million a year earlier.
GAAP diluted EPS was $0.86, up from $0.63, while non-GAAP diluted EPS was $2.63, down from $2.70; non-GAAP operating income was $292.0 million, down 3.9%.
Acquisition-related, integration and restructuring expenses were $65.5 million in the quarter, versus $16.8 million a year earlier.
Third-quarter non-GAAP diluted EPS is expected at $2.65 to $2.77; the quarterly dividend of $0.36 per share is payable August 4, 2026.
Zimmer Biomet signed a new $1.5 billion five-year unsecured revolving credit agreement and a $1.25 billion 364-day unsecured revolving credit agreement, both dated June 26, 2026, with JPMorgan Chase Bank as administrative agent. The company said the borrowings will fund general corporate purposes and terminated its two prior revolving facilities dated June 27, 2025, which had no balance outstanding. The filing describes the new facilities as financing arrangements that carry covenants, including a maximum consolidated indebtedness to EBITDA ratio of 4.5 to 1.0.
Five-year facility of $1.5 billion matures June 26, 2031, with an uncommitted feature to increase it by up to $750.0 million
364-day facility of $1.25 billion matures June 25, 2027
Both agreements require a consolidated indebtedness to EBITDA ratio of no greater than 4.5 to 1.0
Prior 2025 facilities were terminated June 26, 2026; about $0.4 million in fees were paid in cash
Copart's board appointed Executive Chairman A. Jayson Adair as chief executive effective July 31, 2026, replacing Jeffrey Liaw, who will also resign from the board. The filing discloses a transition agreement for Liaw with a $450,000 lump sum, $200,000 paid during a transition period through July 31, 2027, and additional conditional severance and equity benefits, which shareholders may weigh as part of the leadership change.
Adair, who previously led Copart as CEO, takes over on July 31, 2026, and Liaw steps down as CEO and director on the same date.
Liaw's transition agreement provides a $450,000 lump sum and $200,000 during the transition period, subject to a general release.
Liaw's conditional severance includes $250,000, accelerated vesting of remaining equity awards, and an extension of stock option exercise periods.
Adair is the son-in-law of Chairman Wills J. Johnson, a relationship the filing says is disclosed in the 2025 proxy statement.
Fortune Brands Innovations appointed Jesse Singh, former CEO of The AZEK Company, as chief executive and a board member, effective June 29, 2026. Interim CEO David Barry was named Executive Vice President and Chief Operating Officer, and the company has begun a strategic review of its Fiberon business.
Singh's base salary is $1,100,000, with a bonus target of 150% of salary and an annual long-term incentive target of $6,700,000.
Singh's inducement awards, granted July 1, 2026, cover 850,000 performance-based RSUs and a 300,000-share stock option award.
Barry receives a performance-based RSU award with a target grant value of $1,200,000 and a 25,000-share option award as COO.
Interim CFO Ashley George will remain in her role while the search for a permanent CFO continues.
SandRidge Energy's subsidiary signed a purchase agreement on June 26, 2026, to acquire oil and gas properties in the Cherokee Play from Rockies Resources Holdings LLC for $65 million in cash, plus three contingent earn-out payments of $2 million each. The company expects to fund the deal with cash on hand and close it in the third quarter of 2026, subject to customary closing conditions. The filing does not report financial results from the assets, so shareholders have no figures yet on how the deal will affect revenue or earnings.
Cash consideration of $65 million at closing, subject to customary purchase price adjustments
Three contingent earn-out payments of $2 million each, tied to WTI crude oil price thresholds from July 1, 2026 through December 31, 2027
Acquired assets include net production of about 3.0 MBoed (about 43% oil), about 7,000 net leasehold acres, interests in 21 wells and eight proven development locations
Expected closing in the third quarter of 2026; the press release says the effective date is May 1, 2026
JATT II Acquisition Corp., a blank check company, entered a business combination agreement with Talawar Tx Inc., a biotechnology developer of bispecific antibodies. The combined company is expected to trade on Nasdaq as TLWR and to receive up to $285 million before transaction costs, including a $225 million PIPE financing at $10.00 per share, if there are no redemptions by JATT II shareholders.
Business combination agreement signed June 29, 2026; JATT II shareholders must approve the deal, and closing is expected in the second half of 2026
Expected proceeds of $285 million before transaction costs, assuming no redemptions: $60 million from the JATT II trust account plus a $225 million PIPE
Combined company expected to trade on Nasdaq Capital Market under ticker TLWR; lead asset TALA-125 targets clinic entry in Q1 2027
Rocket Lab agreed on June 28, 2026 to acquire Iridium Communications in a cash and stock deal valued at $54 per Iridium share and an enterprise value of about $8.0 billion. Iridium holders would receive $27.00 in cash plus Rocket Lab stock, with the stock portion set by an exchange ratio that is subject to a collar between $67.50 and $112.50 per Rocket Lab share. The deal requires Iridium shareholder approval and regulatory clearances and is expected to close in mid-2027, and it is funded partly by a $3.6 billion bridge loan commitment.
Iridium holders receive $27.00 in cash plus Rocket Lab shares at an exchange ratio that is fixed at 0.4000 if the Rocket Lab price is $67.50 or below and at 0.2400 if it is $112.50 or above.
Iridium would pay Rocket Lab a $223.62 million termination fee in specified circumstances, including if its board withdraws support for the deal.
Rocket Lab has a 364-day senior secured bridge term loan commitment of $3.6 billion from Deutsche Bank and Wells Fargo.
The transaction is expected to close in mid-2027 and must be approved by a majority of Iridium's outstanding shares.
Neurogene released updated Phase 1/2 results for its NGN-401 gene therapy in females with Rett syndrome, reporting 47 developmental milestones gained across 10 participants with follow-up of 12 to 30 months. The company reported no plateau or loss of milestones and no new treatment-related serious adverse events since its October 2025 data cutoff. The filing contains clinical data only, with no financial results or guidance changes, and topline results from the Embolden registrational trial are expected in the second half of 2027.
47 total developmental milestones gained across 10 participants, an average of 4.7 per participant, as of the June 16, 2026 data cutoff
Follow-up ranged from 12 to 30 months, with no plateau observed and no milestones lost
No new treatment-related serious adverse events reported since the October 2025 data cutoff; no treatment-related SAEs or DLTs in Embolden as of June 16, 2026
Embolden registrational trial dosing is complete with 25 participants; topline results expected in 2H 2027
PVH Corp. entered into a new credit agreement dated June 24, 2026, with Bank of America, N.A. as administrative agent. The company used proceeds from a €400 million euro term loan to repay in full its existing credit agreement from December 9, 2022, which was then terminated. The new facilities mature on June 24, 2031 and give the company access to a $1.5 billion revolving credit line, adding a new debt obligation to its balance sheet.
Euro term loan A of €400 million borrowed by PVH B.V. on June 24, 2026, with the company's proceeds used to repay the 2022 credit agreement
$1.5 billion multicurrency revolving credit facility, with the company and PVH B.V. as borrowers
Both facilities mature June 24, 2031; term loan amortizes at 2.50% per year starting with the quarter ending September 30, 2026
Agreement includes a maximum net leverage ratio covenant and a change-in-control event of default
Terra Property Trust, Inc. announced the final results of its exchange offer for its unsecured 6.00% Senior Notes due June 30, 2026. Holders tendered $36,208,750 in principal, or 66.4% of the outstanding notes, as of the June 26, 2026 expiration date, and the exchange remains subject to the conditions in the prospectus.
Tendered principal: $36,208,750, or 66.4% of the outstanding 6.00% Senior Notes due June 30, 2026, as of 5:00 p.m. New York time on June 26, 2026
Offer terms: exchange for new 11.00% Senior Secured Notes due July 1, 2027 plus cash
Registration statement on Form S-4 declared effective by the SEC on June 26, 2026
Completion is subject to the conditions in the prospectus; Ladenburg Thalmann & Co. Inc. was dealer manager
On June 28, 2026, Iridium agreed to merge with Rocket Lab, which will acquire all outstanding Iridium common stock for $27.00 in cash plus Rocket Lab shares per Iridium share. The companies put the notional value at $54.00 per share and the enterprise value at approximately $8.0 billion, and the deal requires an Iridium stockholder vote, antitrust clearance, and FCC consent. Iridium would owe Rocket Lab a $223.62 million termination fee in specified circumstances, and its shares would be delisted from Nasdaq if the deal closes.
Each Iridium share receives $27.00 in cash plus Rocket Lab stock; the exchange ratio is fixed at 0.4000 if the Rocket Lab price is $67.50 or less and at 0.2400 if it is $112.50 or more.
The transaction is expected to close in mid-2027, with an outside date of June 28, 2027, extendable to December 28, 2027.
Iridium would pay Rocket Lab a $223.62 million termination fee under specified circumstances, including if its board withdraws its recommendation.
Rocket Lab has received commitments for a $3.6 billion 364-day senior secured bridge term loan from Deutsche Bank and Wells Fargo.
BioCryst said its board approved on June 25, 2026 a plan to discontinue internal discovery programs and close its Birmingham, Alabama facility, with the work substantially complete by the end of 2026. The company cannot yet estimate the total cost of the plan and will file an amendment once it does, while lowering its 2026 non-GAAP operating expense guidance and reaffirming revenue guidance.
Board approved the plan on June 25, 2026; implementation expected to be substantially complete by the end of 2026.
Total costs of the plan are not yet estimated; expected costs include contract, lease and employee termination and severance.
2026 non-GAAP operating expense guidance lowered to $420 million to $440 million from $450 million to $470 million.
Total 2026 revenue guidance of $635 million to $660 million is reaffirmed; ORLADEYO oral pellets expected to be available in early August 2026.
Honeywell completed the spin-off of its Aerospace business effective 12:01 a.m. New York time on June 29, 2026, making Honeywell Aerospace Inc. an independent public company that began regular-way trading on Nasdaq that day. The 8-K also covers agreements with Honeywell on separation, transition services, taxes, employee matters, intellectual property and trademarks, and supplemental unaudited quarterly results for 2024 and 2025 showing full-year 2025 net sales up but net income attributable to the company down.
Distribution: one share of Honeywell Aerospace common stock for every two Honeywell common shares held at the close of business on June 15, 2026; fractional shares were sold and cash paid instead.
Trading began on Nasdaq under HONA on June 29, 2026, with CUSIP 43849R105. Honeywell continues as Honeywell Technologies.
FY 2025 net sales were $17,404 million versus $15,445 million in FY 2024, while net income attributable to Honeywell Aerospace was $2,687 million versus $2,817 million.
Genesco said Jonathan Collins will become Senior Vice President, Finance and Chief Financial Officer on August 3, 2026, and serve as principal financial officer from that date. Board Chair, President and CEO Mimi E. Vaughn, who has been interim CFO since March 2026, will stop serving in that role on the same date. The filing sets out Collins' pay package, which includes a $550,000 base salary and a $1,787,500 initial total direct compensation at target.
Collins' annual base salary is $550,000, with a Fiscal 2027 short-term incentive target of $412,500 and a long-term incentive target of $825,000.
Collins previously served as CFO of America's Car-Mart, Inc. from May 2025, and spent 2012 to 2025 at Walmart Inc., including as CFO of Walmart Africa.
Vaughn, who served as interim CFO since March 2026, will no longer be interim CFO or principal financial officer as of August 3, 2026.
Collins will receive a $25,000 quarterly relocation stipend, payable for three quarters.
Honeywell completed the spin-off of its Aerospace Technologies business, which now operates as Honeywell Aerospace (HONA), effective June 29, 2026. The parent now operates as Honeywell Technologies and continues to trade on Nasdaq as HON, and a 1-for-2 reverse stock split of its common stock took effect the same day. Shareholders should note the parent no longer consolidates Aerospace and that the share count was halved.
Spin-off effective 12:01 a.m. New York City time on June 29, 2026; Honeywell Aerospace began regular-way trading on Nasdaq as HONA that day.
Distribution ratio was one Aerospace share for every two Honeywell shares held at the close of business on the June 15, 2026 record date.
Reverse split reduced shares outstanding from about 634 million (March 31, 2026) to about 317 million; authorized shares cut from 2 billion to 1 billion.
Exhibit 99.2 recasts results: continuing-operations segment profit was $944 million in Q1 2026 versus $793 million in Q1 2025, and CEO James Currier resigned as an executive officer to lead Honeywell Aerospace.
Larimar Therapeutics said it has submitted the first module of a rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp, after FDA meeting minutes said the existing data package appears sufficient for submission. The company also reported longer-term open label data, which showed improvements in some clinical measures alongside anaphylaxis in 10 of 43 patients, a safety finding shareholders should weigh.
First module of the rolling BLA submitted; remaining modules expected in the second half of 2026.
FDA meeting minutes say the existing data package appears sufficient for a BLA seeking accelerated approval; approval will be a matter of review.
Anaphylaxis occurred in 10 of 43 patients in the open label study, 9 of whom had prior exposure to nomlabofusp.
At 1 year, 100% (9/9) of participants had skin FXN levels above 50% of healthy volunteer mean; first patient dosing in a global Phase 3 study is expected in Q3 2026.
Atlas Lithium said the Minas Gerais permitting commission voted on June 26, 2026 to grant its expansion permit, applied for on November 25, 2024, and the decision was published in the state gazette on June 27, 2026. The permit covers additional mining areas and authorizes assembling and operating its lithium processing plant, processing mined ore there, and selling the lithium concentrate it produces, which the company says positions it to advance its Neves Project.
Permitting commission vote granting the expansion permit: June 26, 2026
Official gazette publication in Minas Gerais, Brazil: June 27, 2026
Permit covers additional mining areas beyond those in the operational permit received October 25, 2024
Permit authorizes plant assembly and operation, ore processing, and sale of lithium concentrate
Verizon signed a transaction agreement on June 28, 2026 with BT Group and NewCo to combine its international wireline connectivity and managed network services business with BT's equivalent business, with each company holding 50% of NewCo. Verizon will also make a $625 million cash payment to NewCo, which will pass it to BT, and it expects a second-quarter 2026 estimated loss of $700 million to $800 million, plus severance and asset charges, that will weigh on reported results.
Transaction agreement signed June 28, 2026; closing is subject to customary regulatory approvals and closing conditions.
Verizon to pay $625 million in cash to NewCo; the value of each contributed business is subject to adjustment for cash, net working capital and indebtedness at closing.
Expected second-quarter 2026 estimated loss of $700 million to $800 million from classifying the Verizon Contributed Business as held for sale.
Severance charge of $350 million to $450 million and asset rationalization charges of $200 million to $300 million expected in the second quarter of 2026.
Mexco Energy Corporation reported results for the fiscal year ended March 31, 2026, in a June 29, 2026 news release furnished under Item 2.02. Net income fell 24% from fiscal 2025 and operating revenues fell 8%, which the company attributed mainly to lower average realized oil prices and reduced oil production volumes.
Net income of $1,305,722, or $0.64 per diluted share, down 24% from fiscal 2025
Operating revenues of $6,561,324, down 8%, driven by lower oil prices and reduced oil production
Cash on hand of approximately $1.4 million and no outstanding debt under the bank line of credit
Company expects to participate in 33 horizontal wells in fiscal 2027, at an estimated aggregate cost of approximately $1.8 million
On June 27, 2026, Korn Ferry agreed to acquire AMS, a talent and consulting firm, for about £850 million (about $1.1 billion), with about $881 million in cash and about $255 million in Korn Ferry common stock. Closing requires regulatory approvals and is expected in the fiscal quarter ending October 30, 2026. Shareholders will see new shares issued and cash funded partly by revolver borrowings, and the company expects the deal to be immediately accretive to earnings per share in the first full year after adjusting for restructuring, integration and transaction costs.
Total price is about £850 million (about $1.1 billion): about $881 million in cash and about $255 million in Korn Ferry shares.
Cash funding is about $300 million from cash on hand and about $581 million from borrowings under the existing revolver.
AMS has about $650 million of run-rate fee revenue and $100 million of Adjusted EBITDA, according to the press release.
Closing requires HSR waiting period expiry and UK and German approvals, and may be terminated if conditions are not met within 180 days of signing.
Creative Realities began an underwritten public offering of common stock and pre-funded warrants on June 29, 2026, with Craig-Hallum as sole managing underwriter. The company also estimated unaudited second-quarter 2026 revenue of $21.0 million to $23.0 million and Adjusted EBITDA of $2.0 million to $2.2 million, and warned that final results may differ materially.
Underwritten offering of common stock or pre-funded warrants announced June 29, 2026; the offering is subject to market conditions and its size and terms are not final.
Underwriter has a 30-day option to buy up to an additional 12.5% of the shares offered.
Preliminary Q2 2026 estimates: revenue $21.0 million to $23.0 million; Adjusted EBITDA $2.0 million to $2.2 million, a margin of about 10.0%. Figures are unaudited and not reviewed by Grant Thornton LLP.
Net proceeds are intended for working capital, general corporate purposes, debt paydown and potential acquisitions.
Decoy Therapeutics entered into a securities purchase agreement on June 26, 2026 to sell 592,217 shares of common stock at $5.91 per share to one institutional investor, with closing expected on or about June 29, 2026. The deal also includes milestone-based warrants that could bring up to about $17.5 million more in gross proceeds if exercised, which would add to existing shareholder dilution and depends on future milestones and stockholder approval.
Expected gross proceeds of about $3.5 million before placement agent fees and offering expenses
592,217 shares priced at $5.91 per share, with pre-funded warrants available to the investor in lieu of shares
Series A, B and C milestone warrants could add up to about $17.5 million if fully exercised after milestones and stockholder approval
Placement agent Curvature Securities receives a 9.0% cash fee; a resale registration statement is due within 15 calendar days of the registration rights agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.